Preclinical Development of [211At]meta- astatobenzylguanidine ([211At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma
Abstract
[131I]meta-iodobenzylguanidine ([131I]MIBG) is a targeted radiotherapeutic administered systemically to deliver beta particle radiation in neuroblastoma. However, relapses in the bone marrow are common. [211At]meta-astatobenzylguanidine ([211At] MABG) is an alpha particle emitter with higher biological effectiveness and short path length which effectively sterilizes microscopic residual disease. Here we investigated the safety and antitumor activity [211At]MABG in preclinical models of neuroblastoma.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jul 21, 2022
- Source ID
- 10.1158/1078-0432.ccr-22-0400
Entities
People
- Bruce Pawel
- Catherine Hou
- Daniel A. Pryma
- Daniel Martinez
- David Groff
- Ganesan Vaidyanathan
- Jimmy Elias
- John M. Maris
- Matthew Tsang
- Mehran Makvandi
- Minu Samanta
- Paul Martorano
- Pietro Ranieri
- Sean Carlin
- Vandana Batra
- Yimei Li
Organizations
- Children's Hospital of Philadelphia
- Duke University Hospital
- National Institutes of Health
- United States Department of Defense
- University of Pennsylvania
- University of Southern California